SeQure Dx Emerges From Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies
SeQure Dx, a cutting-edge gene editing diagnostics company, has announced its emergence from stealth mode with an aim to partner with biopha
Active portfolio
Active portfolio in the news
- Nov 15
Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award
LYNX™ drug delivery platform was named the winner of the 2022 Fierce Life Sciences Innovation Award in the Drug Delivery Technology category
- Nov 15
ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma
ZielBio announced that the U.S. FDA has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of cholangiocarcinoma
- Nov 15
Garuda Therapeutics Announces Appointment of David DiGiusto, PhD, as Chief Technology Officer
Garuda, a company creating off-the-shelf, durable blood stem cell therapies, announces appointment of David DiGiusto, PhD, as CTO
- Oct 17
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with hearing loss
- Oct 14
Amolyt Pharma Announces Positive Safety and Efficacy Results from Phase 2A Trial of AZP-3601
Results from both cohorts support advancement of AZP-3601 into a Phase 3 trial next year
- Oct 10
Walden Biosciences Appoints Peter Guest Linde, M.D. as Chief Medical Officer
Experienced nephrologist brings extensive clinical leadership and industry expertise to drive transformational approaches to treating kidney
- Oct 6
Pediatric mental health startup launches with $26M and a vow to scale Mass General’s care model
nStride Health — a virtual care provider for pediatric patients with moderate to severe anxiety and OCD — recently launched with $26 million
- Sep 27
New Mental Health Company to Revolutionize Mental Health Care Delivery for Seniors
Rippl raises $32 Million to build the future of mental health care for seniors
- Sep 21
Endpoints News Announces the 11 Most Promising Biotech Startups of 2022
Rome Therapeutics has been named to the Endpoints 11 list of most promising biotech startups of 2022
- Sep 11
Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program
Keros Therapeutics presented clinical data from the Part 2 multiple ascending dose portion of its Phase 1 clinical trial of KER-012
- Sep 11
Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study
During three months of treatment with AZP-3601, mean serum calcium levels were maintained within the target range and allowed for the discon
- Sep 11
Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022
Scorpion Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies
- Sep 7
Photys Therapeutics Debuts with $75 Million Series A Funding
Photys Therapeutics debuts with $75 Million Series A to advance new class of bifunctional molecules for precision phosphorylation
- Sep 6
Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer
Garuda Therapeutics (Garuda) today announced the appointment of Roger Sawhney, M.D., as Chief Financial Officer.
- Jul 20
In Quest for Liver Disease Gene Therapy Vertex Invests $340M in Verve
Massachusetts-based biopharma companies Vertex and Verve Therapeutics entered into exclusive four-year research partnership
- Jun 8
Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin
Funded by grant from Bill & Melinda Gates Foundation, Lyndra answers WHO’s call to investigate ivermectin as malaria eradication strategy.
- May 31
Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601
Amolyt Pharma announces positive results from clinical proof of concept trial of AZP-3601, which is being developed as a potential treatment
- May 17
SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies
SwanBio Therapeutics announced the completion of a $56M Series B financing round, led by Syncona Limited and Mass General Brigham Ventures
- Mar 16
Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601
Top-line safety and efficacy data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022